Cargando…
Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
Currently several combination treatments of mTor- and Ras-pathway inhibitors are being tested in cancer therapy. While multiple feedback loops render these central signaling pathways robust, they complicate drug targeting. Here, we describe a novel H-ras specific feedback, which leads to an inadvert...
Autores principales: | Posada, Itziar M.D., Lectez, Benoit, Sharma, Mukund, Oetken-Lindholm, Christina, Yetukuri, Laxman, Zhou, Yong, Aittokallio, Tero, Abankwa, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546501/ https://www.ncbi.nlm.nih.gov/pubmed/28562352 http://dx.doi.org/10.18632/oncotarget.17819 |
Ejemplares similares
-
Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1
por: Posada, Itziar M. D., et al.
Publicado: (2017) -
ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold
por: Posada, Itziar M. D., et al.
Publicado: (2016) -
Cancer stem cell drugs target K-ras signaling in a stemness context
por: Najumudeen, A K, et al.
Publicado: (2016) -
Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
por: Siddiqui, Farid Ahmad, et al.
Publicado: (2021) -
Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation
por: Šolman, Maja, et al.
Publicado: (2015)